undamentalytics Newsletter
Sign in

Liminatus Pharma, Inc. (LIMN) stock

Add to watchlist

Add holding +

NASDAQ: LIMN Nasdaq Biotechnology

Liminatus Pharma, Inc. is a US-listed company in the biotechnology industry. Its financial year ends in December.

Who’s trading

What company insiders, investment funds and members of Congress have been doing with the stock, from their own filings.

  • Funds5 adding, 10 cuttingOf 1 active managers that changed their stake, 0 added; quarter to June 30, 2026Fund buyers and sellers

The Fundamentalytics view

Assembled from SEC-filed figures — the full workings are on this page and in our methodology. Observations, not recommendations.

Highlights

How we pick these

Strengths

Nothing in Liminatus Pharma, Inc.'s latest figures clears our strength thresholds.

Things to watch

  • Volatile shares. Over the past year the shares showed annualised volatility of 178% and a beta of 0.3 against the S&P 500.

Price chart

  • 1 day-10.6%
  • 1 week-20.3%
  • 1 month-35.4%
  • This year-91.7%
  • 1 year-96.4%
  • S&P 500 this year+11.2%

Closing prices to 2026-11-02. Price change only, dividends excluded.

Loading chart…

Third-party market data · may be delayed

At a glance

Trailing twelve months, from SEC filings

News & updates

Updated October 31, 2026

Company announcements, filed results and changes that matter to shareholders.

  1. Announcement
  2. Announcement
  3. Shareholder vote
  4. Announcement
  5. Announcement
  6. Deal

Refreshed hourly when new source data is available. Summaries are checked against company releases and SEC filings. Company announcement headlines are labelled when a checked summary is unavailable.

Valuation

Liminatus Pharma, Inc. valuation models and calculator

No model value for Liminatus Pharma, Inc. at the moment. Current status: limited reported history: available models are shown without a Buy/Hold/Sell rating. Available reported financials are shown below.

Fundamentalytics rating

model v1.6 · 2026-11-03

Not rated: limited reported history: available models are shown without a Buy/Hold/Sell rating.

Valuation models

We value Liminatus Pharma, Inc. as an operating company, with every model that fits that kind of business. Cost of equity 9.9%: the 10-year Treasury yield (4.9%) plus a beta of 1.1 times a 4.5% equity risk premium.

Value per share by model
Model Value per share In the combined value?
Price-to-earnings vs peers Earnings per share times peers' typical (harmonic-mean) price-to-earnings. — Does not apply: no twelve-month earnings or share count in the filings yet
Residual income Book value plus the present value of returns above the cost of equity, fading over ten years. — Does not apply: no twelve-month earnings or share count in the filings yet
Justified price-to-book Book value times (return on equity - growth) / (cost of equity - growth): steady-state returns. — Does not apply: no twelve-month earnings or share count in the filings yet
Revenue-to-maturity model Revenue grown to maturity with the cash margin moving to the industry's; for companies not yet profitable. — Does not apply: revenue and margins don't support a positive value
Price-to-sales vs peers Sales per share times peers' typical price-to-sales; used only when earnings are negative. — Does not apply: no twelve-month earnings or share count in the filings yet
Combined value Weighted average of the models that apply: the primary model (price-to-earnings vs peers) counts double. Models more than 5x or less than 0.2x the share price, or more than 3x away from the other models' median, are left out. — No model applies: the filings don’t yet support a value.

Different models fail in different ways, so where several apply we average them rather than trust one. Peer-based models compare Liminatus Pharma, Inc. with Biotechnology in our coverage, using third-party market data. Model values are estimates under stated assumptions, updated as new filings arrive; not price targets or investment advice. How each model works.

Moat

Not assessed: fewer than five years of comparable figures in the filings. AI disruption exposure for this industry: Medium.

A rules-based reading of reported figures, not a forecast and not investment advice. How the score is built: methodology.

Forecasts and guidance

Analysts' consensus

No analyst estimates are published for Liminatus Pharma, Inc.: too few analysts cover it.

Positioning

Short interest
3.7%
of tradable shares
Days to cover
1.73
at average volume
Short interest, 1 month
−33%
to October 15, 2026
Held by institutions
1%
of shares
Held by insiders
27.2%
of shares
Employees
1
full time

Consensus figures average analysts' published estimates (third-party data); guidance is the company's own. Neither is our forecast. Short interest is reported twice a month and lags. Market data may be delayed.

This section is general information, not investment advice or a personal recommendation, and it does not take account of your objectives or circumstances. Forecasts and guidance are estimates, not promises: companies miss their own guidance and analysts' figures are often revised. Prices can fall as well as rise, and you can lose money. See our disclaimer.

Share-price performance

Market data may be delayed

Return and risk by year

Calendar year 2026 to date
Return
LIMN−92%
Industry peers (median)−26%
S&P 500+11%
Months that ended higher
LIMN9%
S&P 50046%
Largest fall from a high during the year
LIMN−98%
S&P 500−9%

Worst fall since May 2, 2025: 100% from June 24, 2025 to November 2, 2026. Getting back needed a 52817% gain, and the shares have not yet recovered.

Price behaviour

52-week range
$2.52 – $102.50
From 52-week high
−97.5%
vs 50-day average
−30.1%
vs 200-day average
−76.9%
Volatility (1 year)
178%
Beta vs S&P 500
0.31

Volatility is the annualised standard deviation of daily returns. Beta 1.5 means the shares typically moved 1.5% for each 1% move in the S&P 500 over the past year. Prices to November 2, 2026.

Fundamentals

Data: SEC EDGAR XBRL company facts (as filed in 10-K/10-Q); forms . Generated November 3, 2026. Definitions in our methodology.

Who owns it

Funds buying and selling
Reported value
$69,097
Institutions reporting
13
Shares held vs prior quarter
▼ 58.2%
Positions opened / closed
4 / 5

Top buyers and sellers, Q2 2026: 5 institutions bought and 10 sold ; the biggest buyer was Xtx Topco Ltd (+222K shares) and the biggest seller Citadel Advisors LLC (−621K). See which funds bought and sold →

Largest reported holders, June 30, 2026
Manager Value Shares Share of 13F value Shares QoQ
Xtx Topco Ltd $24,491 222K 35.4% New
Geode Capital Management, LLC $15,282 138K 22.1% ▲ 17.5%
Citadel Advisors LLC $6,192 56K 9.0% ▼ 91.7%
Vanguard Capital Management LLC $5,548 50K 8.0% 0.0%
Goldman Sachs Group Inc $4,440 40K 6.4% New
Stonex Group Inc. $3,934 26K 5.7% New
Vanguard Fiduciary Trust Co $2,528 23K 3.7% 0.0%
State Street Corp $2,098 19K 3.0% 0.0%
UBS Group AG $1,840 17K 2.7% ▼ 69.3%
Vanguard Personalized Indexing Management, LLC $1,452 13K 2.1% ▼ 62.1%
Tower Research Capital LLC (TRC) $783 7K 1.1% ▼ 6.3%
Barclays PLC $474 4K 0.7% New

From Form 13F filings with the SEC ( quarterly data sets), as reported by each manager for June 30, 2026 and filed up to 45 days later. 13F reports cover long US-listed positions of managers above $100M only, so this is not Liminatus Pharma, Inc.'s complete shareholder register. Values are as reported by the filers .

Insider trading activity

Full insider history and chart
Insider purchases History → $0 0 trades by 0 insiders, last 12 months Insider sales History → $0 0 trades by 0 insiders
Net ▲ $0 net buying

No open-market insider trades reported in the last 12 months.

From insiders' Form 4 filings with the SEC. Excludes awards, option exercises and shares withheld for tax. "Pre-set plan" means the filing marks the trade as made under a Rule 10b5-1 plan. See every insider trade since five years ago, on a price chart.

Earnings dates and SEC filings

Results announcements

Recent SEC filings

Data status

When each part of this page on Liminatus Pharma, Inc. was last updated.

DataLast updatedSource
Share priceExchange closing prices
News and updatesCompany releases and SEC 8-K filings
Analyst estimatesAggregated analyst estimates
Valuation and scoresOur models, from the filed figures

How we build and check these figures: methodology and data sources.

Liminatus Pharma, Inc. in brief

What does Liminatus Pharma, Inc. do?
Liminatus Pharma, Inc. is a US-listed company in the biotechnology industry. Its financial year ends in December.
What is Liminatus Pharma, Inc.'s stock ticker?
Liminatus Pharma, Inc. trades under the ticker LIMN on Nasdaq. This page brings together its financial statements, valuation models, ownership and recent company updates.
Who are Liminatus Pharma, Inc.'s largest institutional shareholders?
By value reported in 13F filings for June 30, 2026, the largest reported holders are Xtx Topco Ltd, Geode Capital Management, LLC and Citadel Advisors LLC. 13F reports cover long US-listed positions of managers above $100M, filed up to 45 days after quarter end.